JIANGSU, China
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for metabolic and inflammatory diseases, such as gout, is calling for increased understanding of the dangers of chronic gout to help mark Gout Awareness Day, May 22, 2024. The company released a video, https://atombp.us/video-gout-awareness-day-2024/ showing hyperuricemia, the cause of gout, can lead to more serious conditions and the company’s efforts to develop a new treatment.
“More than 55 million people suffer from gout worldwide, and its prevalence is increasing yearly,” said William Dongfang Shi, Ph.D., Founder and CEO of Atom Bioscience. “Over 9.3 million people in the U.S. suffer from the disease, and those numbers are expected to rise. The need for new safe and effective treatments has never been greater. Patients also should understand that chronic gout has been linked to many diseases including heart attacks and kidney disease.”
Atom is enrolling patients in the US for a Phase 2b/3 clinical trial of ABP-671, a novel orally administered URAT1 inhibitor, for the treatment of chronic gout (See clinicaltrials.gov NCT05818085).
Gout is one of the most common types of inflammatory arthritis. It is caused by a long-term condition known as hyperuricemia, defined as excessive uric acid levels in the blood (> 7 mg/dL). The build-up of uric acid is caused by genetic mutations in uric acid transport mechanisms in the kidney and bowel.
When the transporters don’t function, uric acid is not properly excreted from the body. Excessive uric acid can lead to the formation of crystals in joints and soft tissues, causing debilitating inflammation and the development of urate kidney stones.
About Atom Bioscience
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.) is a fast-growing innovative drug company, focused on development of best in class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. For more information please visit: https://atombp.us/
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521844793/en/
CONTACT
Media Contact:
Daniel Eramian
Opus Biotech Communications
http://opusbiotech.com/
425-306-8716
